293 related articles for article (PubMed ID: 14578481)
1. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents.
Fizanne L; Sigaudo-Roussel D; Saumet JL; Fromy B
J Physiol; 2004 Jan; 554(Pt 2):519-28. PubMed ID: 14578481
[TBL] [Abstract][Full Text] [Related]
2. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
3. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
4. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
6. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
7. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
8. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
10. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
11. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
Grant S; Lutz EM; McPhaden AR; Wadsworth RM
J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462
[TBL] [Abstract][Full Text] [Related]
12. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
13. Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons.
Sághy É; Payrits M; Helyes Z; Reglődi D; Bánki E; Tóth G; Couvineau A; Szőke É
Neuroscience; 2015 Nov; 308():144-56. PubMed ID: 26321242
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans.
Kellogg DL; Zhao JL; Wu Y; Johnson JM
J Appl Physiol (1985); 2012 Nov; 113(10):1512-8. PubMed ID: 22961270
[TBL] [Abstract][Full Text] [Related]
16. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development.
Basille M; Vaudry D; Coulouarn Y; Jegou S; Lihrmann I; Fournier A; Vaudry H; Gonzalez B
J Comp Neurol; 2000 Oct; 425(4):495-509. PubMed ID: 10975876
[TBL] [Abstract][Full Text] [Related]
17. PAC1 receptors mediate pituitary adenylate cyclase-activating polypeptide- and progesterone-facilitated receptivity in female rats.
Apostolakis EM; Riherd DN; O'Malley BW
Mol Endocrinol; 2005 Nov; 19(11):2798-811. PubMed ID: 15976009
[TBL] [Abstract][Full Text] [Related]
18. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
19. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy.
Dickinson T; Mitchell R; Robberecht P; Fleetwood-Walker SM
Neuropharmacology; 1999 Jan; 38(1):167-80. PubMed ID: 10193908
[TBL] [Abstract][Full Text] [Related]
20. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats.
Koga M; Mizuno Y; Watanabe I; Kawakami H; Goto T
J Appl Physiol (1985); 2014 Aug; 117(4):383-91. PubMed ID: 24947028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
